Home » Authors » Mark Lawson

Articles by Mark Lawson

Alchemia Raises A$15.2M To Expand Research, U.S. Operation

April 4, 2001

Alchemia Raises A$15.2M To Expand Research, U.S. Operation

April 4, 2001

PanBio Seeks A$12M In IPO To Fund Diagnostic Programs

Feb. 28, 2001

PanBio Seeks A$12M In IPO To Fund Diagnostic Programs

Feb. 28, 2001

Medica Strengthens Position With Kinase-Targeting Filings

Feb. 14, 2001

Medica Strengthens Position With Kinase-Targeting Filings

Feb. 14, 2001

Analytica Capitalizes On Taiwan Initiative Through New Subsidiary

Feb. 7, 2001

Analytica Capitalizes On Taiwan Initiative Through New Subsidiary

Feb. 7, 2001

Biotran Completes Australian IPO To Fund Diagnostics, HIV Product

Jan. 24, 2001

Biotran Completes Australian IPO To Fund Diagnostics, HIV Product

Jan. 24, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...